US Stock MarketDetailed Quotes
TNYA Tenaya Therapeutics
- 4.310
- +0.090+2.13%
Close Apr 26 16:00 ET
- 4.310
- 0.0000.00%
Post 16:20 ET
338.41MMarket Cap-2565P/E (TTM)
4.360High4.222Low100.97KVolume4.250Open4.220Pre Close434.86KTurnover0.24%Turnover RatioLossP/E (Static)78.52MShares8.09152wk High2.43P/B184.19MFloat Cap1.66052wk Low--Dividend TTM42.74MShs Float32.000Historical High--Div YieldTTM3.26%Amplitude1.640Historical Low4.306Avg Price1Lot Size
Tenaya Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 2.25%-102.07M | 3.34%-21.92M | 14.22%-23.64M | -3.11%-26.22M | -5.33%-30.29M | -71.72%-104.42M | -38.75%-22.68M | -65.43%-27.56M | -111.58%-25.43M | -82.13%-28.76M |
| Net income from continuing operations | -0.34%-124.08M | 10.68%-29.94M | 5.06%-29.14M | -17.16%-33.27M | -2.19%-31.74M | -70.05%-123.67M | -28.16%-33.52M | -68.09%-30.7M | -86.70%-28.4M | -137.10%-31.06M |
| Depreciation and amortization | 34.33%8.69M | 3.02%2.18M | 4.50%2.18M | 69.24%2.2M | 120.50%2.13M | 118.41%6.47M | 167.64%2.12M | 179.76%2.09M | 76.46%1.3M | 40.20%966K |
| Other non cash items | 35.97%3.35M | -6.48%866K | 18.77%848K | 68.84%829K | 142.77%806K | 118.93%2.46M | 142.41%926K | 131.07%714K | 86.69%491K | 94.15%332K |
| Change In working capital | -565.25%-5.65M | -113.45%-671K | 53.95%-1.22M | 135.15%683K | -259.19%-4.44M | -117.90%-849K | -33.17%4.99M | -521.03%-2.66M | -214.90%-1.94M | 68.99%-1.24M |
| -Change in prepaid assets | 103.44%101K | -655.81%-1.91M | 145.07%1.28M | 131.37%367K | -50.00%366K | -7.47%-2.93M | 15.05%344K | 9.03%-2.84M | -4,580.00%-1.17M | 520.34%732K |
| -Change in payables and accrued expense | -117.08%-1.03M | -60.92%2.25M | -191.25%-1.51M | 4,171.15%2.22M | -172.83%-3.99M | -49.49%6.01M | -24.69%5.76M | -43.20%1.66M | -97.00%52K | -261.63%-1.46M |
| -Change in other current assets | 26.26%-601K | 139.86%57K | 112.59%68K | -466.24%-889K | 552.00%163K | 73.83%-815K | -180.39%-143K | -395.41%-540K | -143.73%-157K | 100.75%25K |
| -Change in other current liabilities | -32.63%-4.12M | -9.55%-1.07M | -13.37%-1.06M | -52.10%-1.02M | -84.37%-979K | -137.43%-3.11M | -124.42%-974K | -720.18%-935K | -77.19%-668K | -38.28%-531K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 2.25%-102.07M | 3.34%-21.92M | 14.22%-23.64M | -3.11%-26.22M | -5.33%-30.29M | -71.72%-104.42M | -38.75%-22.68M | -65.43%-27.56M | -111.58%-25.43M | -82.13%-28.76M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -41.76%48.72M | -349.73%-14.92M | -1.76%30.49M | -16.96%25.09M | -50.95%8.06M | 135.06%83.65M | 109.55%5.97M | 118.43%31.03M | 1,033.56%30.21M | 480.15%16.43M |
| Net PPE purchase and sale | 93.99%-1.24M | 50.44%-394K | 99.80%-8K | 97.10%-208K | 92.68%-629K | 17.88%-20.63M | 93.67%-795K | 18.85%-4.06M | -121.76%-7.18M | -98.82%-8.6M |
| Net investment purchase and sale | -52.07%49.98M | -314.57%-14.51M | -13.10%30.5M | -32.37%25.28M | -65.23%8.7M | 148.85%104.27M | 113.51%6.76M | 121.48%35.1M | --37.39M | --25.03M |
| Net other investing changes | -412.50%-25K | ---18K | ---4K | --9K | ---12K | --8K | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -41.76%48.72M | -349.73%-14.92M | -1.76%30.49M | -16.96%25.09M | -50.95%8.06M | 135.06%83.65M | 109.55%5.97M | 118.43%31.03M | 1,033.56%30.21M | 480.15%16.43M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -94.79%4.05M | -99.52%371K | 0 | 1,507.31%4.18M | -3,440.00%-501K | -62.79%77.77M | 369,080.95%77.49M | -100.00%6K | 120.03%260K | -99.93%15K |
| Net common stock issuance | -95.00%3.87M | --0 | --0 | ---- | ---- | -58.95%77.39M | 121,017.19%77.39M | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 79.47%682K | 274.75%371K | --0 | 19.62%311K | --0 | 1.60%380K | 219.35%99K | -97.88%6K | 738.71%260K | -48.28%15K |
| Net other financing activities | ---501K | --0 | --0 | --0 | ---501K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -94.79%4.05M | -99.52%371K | --0 | 1,507.31%4.18M | -3,440.00%-501K | -62.79%77.77M | 369,080.95%77.49M | -100.00%6K | 120.03%260K | -99.93%15K |
| Net cash flow | ||||||||||
| Beginning cash position | 147.37%95.67M | 137.40%82.84M | 141.92%75.99M | 176.62%72.94M | 147.37%95.67M | -70.04%38.68M | -70.34%34.89M | -72.06%31.41M | -79.56%26.37M | -70.04%38.68M |
| Current changes in cash | -186.51%-49.31M | -160.01%-36.47M | 96.61%6.85M | -39.60%3.04M | -84.69%-22.73M | 163.04%57M | 176.98%60.78M | -32.90%3.48M | 130.45%5.04M | -12,587.63%-12.31M |
| End cash Position | -51.54%46.36M | -51.54%46.36M | 137.40%82.84M | 141.92%75.99M | 176.62%72.94M | 147.37%95.67M | 147.37%95.67M | -70.34%34.89M | -72.06%31.41M | -79.56%26.37M |
| Free cash flow | 17.39%-103.31M | 4.94%-22.32M | 25.22%-23.65M | 18.95%-26.43M | 17.22%-30.92M | -45.53%-125.05M | 18.77%-23.48M | -45.95%-31.62M | -113.74%-32.61M | -85.71%-37.35M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg